• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

    3.505 +0.105 (+3.09%)
    Streaming Delayed Price Updated: 12:35 PM EDT, Aug 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Niagen Bioscience, Inc. - Common Stock

    < Previous 1 2 Next >
    News headline image
    Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
    From Niagen Bioscience, Inc.
    Via Business Wire
    News headline image
    Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Announces Participation in Upcoming Investor Conferences
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
    From Niagen Bioscience, Inc
    Via Business Wire
    Four Stocks at the Intersection of Enzymes, Longevity, and the $400 Billion Wellness Boom (CELV, NAGE, MTEX, CDXS)
    Via AB Newswire
    News headline image
    Niagen Bioscience Increases Share Repurchase Program to $20 Million
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience to Present at the 38th Annual ROTH Conference
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
    EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026
    From Niagen Bioscience, Inc
    Via Business Wire
    News headline image
    Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen
    From Niagen Bioscience, Inc.
    Via Business Wire
    News headline image
    Functional Wellness Stocks Explode as $179 Billion Beverage Market Ditches Sugar for Science
    ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. 
    From Equity Insider
    Via GlobeNewswire
    News headline image
    THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point
    ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. 
    From USA News Group
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.